NCT05331144Active, not recruitingPhase 2
Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid, and Tau in Older Adults (IPAT Study)
Rong Zhang1 site in 1 country180 target enrollmentStarted: October 25, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 180
- Locations
- 1
- Primary Endpoint
- Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ)
Study Overview
Brief Summary
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.
Detailed Description
The IPAT study is a 2-arm open-label randomized controlled trial to assess the effects of intensive pharmacological reduction of high blood pressure (SBP) on brain amyloid and tau protein deposition (Alzheimer's Disease pathology) in older adults who are at high risk for AD and related dementias, that is, those who have high blood pressure, family history of dementia, or subjective memory complaints. Furthermore, IPAT will examine effects of intensive blood pressure lowering on brain volume, perfusion, and neural network connectivity using magnetic resonance imaging (MRI) and cognitive performance.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 60 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 60-85, all races/ethnicities, and both sexes are eligible;
- •Mini-Mental State Exam (MMSE) ≥ 26 to exclude gross dementia; based on clinical judgment, may be rescreened in ≥ 7 days;
- •Individuals with SBP ≥ 130 and SBP ≤ 180 if on 0 or 1 antihypertensive medications; ≥130 and ≤170 on up to 2 medications; ≥130 and ≤160 on up to 3 medications; ≥130 and ≤150 on up to 4 medications. Those on antihypertensives are eligible. If an individual, not treated for hypertension (HTN), has a SBP ≥ 125 mmHg, consider rescreening after 24 hours;
- •Willingness to be randomized into the treatment groups and ability to return to clinic for follow-up visits over 24 months;
- •Fluency in English or Spanish or both, adequate visual and auditory acuity to allow neuropsychological testing;
- •Participants must have a regular healthcare provider.
Exclusion Criteria
- •Clinically documented history of stroke, focal neurological signs or other major cerebrovascular diseases based on clinical judgment or MRI/CT scans such as evidence of infection, infarction, or other brain lesions;
- •Diagnosis of AD or other type of dementia, or significant neurologic diseases such as Parkinson's disease, seizure disorder, multiple sclerosis, history of severe head trauma or normal pressure hydrocephalus;
- •Evidence of severe major depression (GDS ≥ 12, may be rescreened after 12 weeks or longer if evidence of reactive depression or temporary mood disturbances) or clinically significant psychopathology, (e.g., psychosis and schizophrenia); if hospitalized in past year, can be rescreened in 6 months; or presence of a major psychiatric disorder that in the investigator's opinion, could interfere with adherence to research assessments or procedures.
- •Unstable heart disease based on clinical judgment (e.g., heart attack/cardiac arrest, cardiac bypass procedures within previous 6 months and congestive heart failure), or other severe medical conditions;
- •History of atrial fibrillation and evidence on ECG with any of the following: active symptoms of persistent palpitation, dizziness, history of syncope, chest pain, dyspnea, orthopnea, shortness of breath at rest, or paroxysmal nocturnal dyspnea within the past 6 months; resting heart rate of < 30 or > 110 bpm; taking class I or III antiarrhythmic drugs including flecainide, propafenone, dronedarone, sotalol, dofetilide, and amiodarone; or clinical concerns for safely participating in lowering blood pressure.
- •Systolic BP equal or greater than 180 mmHg and/or diastolic BP equal or greater than 110 mmHg, may be rescreened in 1 week.
- •Orthostatic hypotension, defined as the third standing SBP < 100mmHg, may be rescreened after 2 weeks;
- •History of significant autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis or polymyalgia rheumatica;
- •Significant history of alcoholism or drug abuse within the last five years;
- •Uncontrolled diabetes mellitus, defined as hemoglobin A1C > 7.5%, or requiring insulin treatment;
- •Regularly smoking cigarettes within the past year;
- •Pacemaker or other medical device of metal that precludes performing MRI;
- •Women with a potential for pregnancy, lactation/childbearing (2 year post-menopausal or surgically sterile to be considered not childbearing potential);
- •Participant enrolled in another investigational drug or device study, either currently or within the past 2 months;
- •Severe obesity with BMI > 40 ; clinical judgment should be applied in all cases to assess patient safety and anticipated compliance;
- •Allergy to angiotensin receptor blockers (ARBs), i.e., drugs that have a suffix "-sartan"; allergy to amlodipine;
- •Abnormal screening laboratory tests (e.g., liver ALT and AST > 3 x ULN, GFR < 30 or Hct < 28%); may be rescreened after 2 weeks or longer;
- •A medical condition likely to limit survival to less than 3 years;
- •Participant has any condition(s) judged by the study investigator to be medically inappropriate, risky or likely to cause poor study compliance. For example:
- •Plans to move outside the clinic catchment area in the next 2 years;
- •Significant concerns about participation in the study from spouse, significant other, or family members;
- •Lack of support from primary health care provider;
- •Residence too far from the study clinic site such that transportation is a barrier including persons who require transportation assistance provided by the study clinic funds for screening or randomization visits;
- •Residence in a nursing home; persons residing in an assisted living or retirement community are eligible if they meet the other criteria;
- •Other medical, psychiatric, or behavioral factors that, in the judgment of the site PI or clinician, may interfere with study participation or the ability to follow the study Protocol.
- •Couples or significant partners who live together cannot be enrolled or participate simultaneously in the study.
Arms & Interventions
Usual Care (UC)
Active Comparator
Participants will follow their PCP's recommendations for BP control
Intervention: PCP (Other)
Intensive Treatment (IT)
Experimental
Lowering SBP < 120 mmHG
Intervention: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) (Drug)
Outcomes
Primary Outcomes
Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ)
Time Frame: Baseline, 24 months
Brain Aβ will be measured by annual change of amyloid mean cortical standardized uptake value ratio (SUVR) with positron emission tomography (PET).
Secondary Outcomes
- Change From Baseline in global Cerebral Blood Flow (CBF)(Baseline, 12 months, 24 months)
- Change From Baseline in regional Cerebral Blood Flow (CBF)(Baseline, 12 months, 24 months)
- Change From Baseline in Neurocognitive Function(Baseline, 12 months, 24 months)
- Change From Baseline in Brain Tau Deposition(Baseline, 24 months)
- Change From Baseline in Arterial Stiffness(Baseline, 12months, 4 months)
- Change From Baseline in Brain Neural Network Connectivity(Baseline, 12 months, 24 months)
- Change From Baseline in Amplitude of Low Frequency Fluctuations of Blood-Oxygen-Level-Dependent Signal (BOLD ALFF)(Baseline, 12 months, 24 months)
- Change From Baseline in White Matter Hyperintensity Volume(Baseline, 12 months, 24 months)
Investigators
Rong Zhang
Professor of Medicine
University of Texas Southwestern Medical Center
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) StudyBlood PressureNCT05352633China National Center for Cardiovascular Diseases710
Completed
Not Applicable
Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) StudyHypertensionNCT04030234China National Center for Cardiovascular Diseases11,255
Completed
Not Applicable
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older PeopleHypertension, SystolicCerebrovascular DiseaseNCT01650402UConn Health199
Terminated
Phase 4
Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular UltrasoundHypertensionCoronary Artery DiseaseNCT01230216Takeshi Morimoto8
Completed
Not Applicable
Systolic Blood Pressure Intervention TrialHypertensionNCT01206062National Heart, Lung, and Blood Institute (NHLBI)9,361